Thursday, January 15, 2026

2 months
AI model identifies improved cancer outcomes globally (38) hot
AI Innovations in Cancer
Clinical Advances & Trials
Policy & Advocacy Collaborations
Other Developments
2 months
Compounding Pharmacy Sues Lilly and Novo Nordisk (4)
2 months
Eli Lilly and Nvidia Launch $1B AI Co‑Innovation Lab (2)
2 months
FDA Removes Suicide Warnings from GLP‑1 Drugs (8)
2 months
HHS reverses $2B mental health addiction grants cut amid policy flip-flop (8)


In Detail Full day, Thursday, January 15, 2026, Timezone: America/Chicago

AI Model Identifies How Every Country Can Improve Its Cancer Outcomes / ESMO

esmo - For the first time, researchers have used machine learning – a type of artificial intelligence (AI) – to identify the most important drivers of cancer survival in nearly all the countries in the world

#healthcare #publichealth #governmentpolicy #biotech


AI Innovations in Cancer

Soha Ahmed Salem: Leading a Powerful AI Collaboration to Improve Cancer Care in LMICs

2 months / oncodaily

AstraZeneca Buys Modella AI: Why Biomarkers, Not Molecules, Are the Real Prize

2 months / oncodaily

Nikhil Vasdev: AI, Imaging, and Genomics Offer Potential to Improve Bladder Cancer Detection and Personalization

2 months / oncodaily

Douglas Flora Discusses AI in Cancer on Chadi Nabhan’s Healthcare Unfiltered

2 months / oncodaily

How AI is transforming health care

2 months / medicalxpress

AI Model Identifies How Every Country Can Improve Its Cancer Outcomes

2 months / esmo

AI model identifies how every country can improve its cancer outcomes

2 months / medicalxpress


Clinical Advances & Trials

Vitamin A may be helping cancer hide from the immune system

2 months / sciencedaily

Suhani: Single Agent ICG vs Dual Dye-Tracer for Sentinel Lymph Node Biopsy in Breast Cancer

2 months / oncodaily

Erdinç Nayır: 3 vs 6 Months of Adjuvant Chemotherapy in Colorectal Cancer

2 months / oncodaily

Vivek Subbiah: Rethinking Cancer of Unknown Primary in the Precision Oncology Era

2 months / oncodaily

Stephanie Haddad: Optimizing Fertility Preservation for AYA Patients – Poster at SCHD26

2 months / oncodaily

Narjust Florez: Community Outreach for EGFR+ Lung Cancer Study in Lawrence

2 months / oncodaily

Stephen V Liu: Results from NRG LU005 Phase III trial

2 months / oncodaily

Thor Halfdanarson: Cabozantinib Shows PFS and ORR Benefit in Grade 3 Neuroendocrine Tumors

2 months / oncodaily

A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI

2 months / esmo


Other Developments

Anirban Maitra: The Most Highly Cited Paper of the Year is Out

2 months / oncodaily


Policy & Advocacy Collaborations

David Collingridge: The Lancet Oncology Collaborates with St Jude for World Cancer Day Webinar

2 months / oncodaily

Tedros Adhanom Ghebreyesus: Cervical Cancer Can Be the First Cancer to Be Eliminated

2 months / oncodaily

Allison Rosen: Advocates Share What Excited Them Most at ASCO GI 2026

2 months / oncodaily

Thomas Hofmarcher: Cancer Dashboard for Serbia Has Been Released

2 months / oncodaily


All Other Stories

AI tool predicts cancer metastasis risk using gene expression signatures

7 wks / medicalxpress

Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection

7 wks / oncodaily

That Cancer Conversation Podcast Season 4: Ep.2 ‘Could AI help us beat cancer?’

7 wks / cancerresearchuk / Cancer Research UK

Spotting skin cancer sooner with the help of AI

7 wks / medicalxpress

Shane O’Hanlon: Managing Multimorbidity in Older People with Cancer

7 wks / oncodaily

Scientists solve a major roadblock holding back cancer cell therapy

7 wks / sciencedaily

Validation of histopathology-based deep learning algorithms for detection of actionable non-small cell lung cancer biomarkers

1 month / nature

George Calin: A Translational Perspective on MicroRNAs in Oncology in the Era of AI

1 month / oncodaily

Hui Huang: Could the ‘g Value’ Transform How We Evaluate Solid Tumor Trials?

1 month / oncodaily

UroFusion-X: a unified multimodal deep learning framework for robust diagnosis, subtyping, and prognosis of urological cancers

1 month / nature

Sabine Brookman-May: Impact of Computational Histology AI Biomarkers on NMIBC Treatment Decisions

1 month / oncodaily

Adrian Lee: Re-imagining Precision Oncology as a Learning System

1 month / oncodaily

Giuseppe Banna: Multimodal Innovation Advances Precision Decision-Making in Bladder Cancer

1 month / oncodaily

Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection

1 month / nature

New Research in Annals of Oncology Shows Machine Learning Revelation of Global Cancer Trend Drivers

1 month / oncodaily

Eliezer Van Allen: Augmenting LLMs with Constantly Evolving Precision Oncology Knowledge

1 month / oncodaily

Leora Horn: Using AI-Driven Digital Biomarkers to Identify the Right Patients

2 months / oncodaily

Thursday, January 15, 2026, 4:21 pm / permalink 17950 / 38 stories in 2 months


Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech

Stephen Liu: What GLP-1 Therapies May Mean for Cancer Risk

7 wks / oncodaily

#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

2 months / endpoints / Andrew Dunn

A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit

2 months / endpoints / Shelby Livingston

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

2 months / beckershospitalreview / Ella Jeffries

Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 2 months


NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily

oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]

#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery

2 months / oncodaily

Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory

2 months / endpoints / Andrew Dunn

Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 2 months


FDA moves to remove suicide warnings from GLP-1 weight loss drugs / Medical Express

medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #governmentpolicy #fda

Physician-Journalist Shines Light on Measles Upsurge and New GLP-1 Study

1 month / kffhealthnews

What Merck’s Chief Medical Officer Thinks of Lilly’s Approach to GLP-1s

2 months / medcitynews / Arundhati Parmar

Long-term GLP-1 use trims medical cost growth: Aon

2 months / beckershospitalreview / Elizabeth Casolo

GLP-1s tied to improved survival in colorectal cancer

2 months / beckershospitalreview / Paige Twenter

FDA moves to remove suicide warnings from GLP-1 weight loss drugs

2 months / medicalxpress

Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

2 months / nature / Atul Malhotra

FDA moves to strike suicide risk warnings from 3 GLP-1s

2 months / beckershospitalreview / Ella Jeffries

FDA asks Lilly, Novo to remove suicide warnings from GLP-1 labels

2 months / endpoints / Zachary Brennan

Thursday, January 15, 2026, 1:23 pm / permalink 17924 / 8 stories in 2 months


H.H.S. Reverses Decision to Cut $2 Billion for Mental Health and Addiction Services / NYT

Jan Hoffman / nytimes - A day after funding termination notices went out to more than 2,000 programs nationwide, the administration reversed itself and reinstated the money.

#trumpadministration #healthcare #publichealth #governmentpolicy

In 24 hours HHS cuts, then restores $2B in addiction and mental health grants

2 months / fiercehealthcare

Whiplash as addiction and mental health treatment gets cut and restored

2 months / npr / Debbie Elliott

Treating addiction with immunotherapy: Study links alcohol use and the immune system

2 months / medicalxpress

US overdose deaths declined in 2025

2 months / beckershospitalreview / Kristin Kuchno

Democrat blasts HHS for creating confusion in cutting, then reinstating SAMHSA grants

2 months / go

The stop-smoking medication varenicline may also work for cannabis use disorder

2 months / medicalxpress

H.H.S. Reverses Decision to Cut $2 Billion for Mental Health and Addiction Services

2 months / nytimes / Jan Hoffman

HHS cancels up to $2B in mental health, addiction grants: 4 federal health updates

2 months / beckershospitalreview / Erica Cerutti

Thursday, January 15, 2026, 1:22 am / permalink 17890 / 8 stories in 2 months


StackHealth Time Machine



Outgoing Stories

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook 14 stories in 16.5 hours

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma 3 stories in 17.5 hours

Vitamin D trial shows reduced long‑COVID risk but no severity benefit 2 stories in 19.5 hours

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival 4 stories in 20.5 hours

FDA approves leucovorin for rare folate disorder despite autism hype 4 stories in 32.5 hours

HORMAD1 emerges as a potential target in triple‑negative breast cancer 4 stories in 45.5 hours

Alfasigma pays $300M to GSK for linerixibat rights, expanding liver-disease portfolio 2 stories in 48.5 hours

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial 5 stories in 49.5 hours

Novo Nordisk and Hims bury the hatchet and carve a deal 3 stories in 54.5 hours

AI improves UK breast-screening detection by about 10% 5 stories in 54.5 hours


More StackHealth

Bluesky:


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.